Allergan is not abandoning R&D in major diseases. Rather, it has 35% of its portfolio in relatively low-risk, lower cost R&D that can sustain its investments in far more challenging therapeutic areas.
from Forbes Real Time http://www.forbes.com/sites/johnlamattina/2017/08/08/allergans-brent-saunders-is-charging-into-medical-aesthetics-should-others-follow/
via IFTTT
No comments:
Post a Comment